IL1B and in situ carcinoma: Especially the secretion of IL-1β from CIS cells was 5- to 10-fold higher than the IL-1β secretion from doxorubicin-treated cells, and even 30- to 80-fold higher than the secretion from palbociclib-treated cells (Figure 5c,d).